<a href=Biotronik” height=”180″ src=”https://www.medicaldevice-network.com/wp-content/uploads/static-progressive/nri/medicaldevice/news/Biotronik_SPG_DEVICE_150812.jpg” style=”padding: 10px” width=”300″ />

Biotronik has reported that the first US patient has been implanted with its Lumax 740 dual-chamber implantable cardioverter defibrillator (ICD).

Lumax 740 dual-chamber ICD features SMART detection, which discriminates between atrial and ventricular arrhythmias and avoid unnecessary therapies.

Reducing unnecessary therapies also reduces the risk for long-term medical consequences that may result from inappropriate shocks, according to the company.

Lumax 740 devices contain Biotronik’s TI feature, which measures thoracic impedance. This provides physicians with information to assist in managing critically important aspects of patient care, including drugs used to adjust fluid levels.

The FDA and CE-approved Biotronik home monitoring technology, which is a feature of the Lumax 740 system, automatically transmits a patient’s clinical and device status on a daily basis.

Biotronik marketing vice president Rex Richmond said the Lumax 740 series’ circuitry design allows the device to last for nearly a decade.

"We know that high quality and durable systems are better for patients and less costly for the healthcare system over time," Richmond said.

Image: Lumax 740 dual-chamber discriminate between atrial and ventricular arrhythmias and avoid unnecessary therapies. Photo: Courtesy of Biotronik USA.